Pestalozzi advises Johnson & Johnson's Swiss based Cilag International on its acquisition of Covagen AG
Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAbtechnology platform. Covagen's lead product, COVA 322, a bispecific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb®, is in Phase 1b study for psoriasis and holds potential as a treatment for a broad range of inflammatory diseases including rheumatoid arthritis. Pestalozzi advised Cilag GmbH International on all Swiss legal and tax aspects of the acquisition.